In:
Mini-Reviews in Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 22, No. 5 ( 2022-03), p. 743-757
Abstract:
Leishmaniasis is a parasitic infectious neglected tropical disease transmitted to humans by
the parasites of Leishmania species. Mainly, three types of leishmaniases are usually observed: visceral (VL), cutaneous (CL), and mucocutaneous leishmaniasis. In many western countries, almost
700,000 to 1 million people suffer from leishma niasis, and it is estimated that around 26000 to 65000
deaths occur from leishmaniasis. Few drugs are available for its treatment; however, none of them are ideal for leishmaniasis due to long treatment, discomfort mode of administration, risk of high-level
toxicity, high resistance, etc. Hence, so many patients are unable to take complete treatment due to the high drug resistance. The present review will focus on antileishmanial activity of reported derivatives
of betacarboline, chalcone, azole, quinoline, quinazoline, benzimidazole, benzadiazapine, thiaazoles, semicarbazone, and hydontoin analogues. We believe that this present study will be helpful for researchers
to design new antileishmanial agents.
Type of Medium:
Online Resource
ISSN:
1389-5575
DOI:
10.2174/1389557521666210913115116
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2022
SSG:
15,3
Permalink